BriaCell Therapeutics Corp. (BCTXW) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
August 13, 2012
| Name | Title | Pay | Year Born |
| William V. Williams | Chief Executive Officer, President & Director | 711,724 | 1955 |
| Charles Louis Wiseman FACP | Founder, Principal Research Advisor & Member of Scientific Advisory Board | 241,138 | 1947 |
| Miguel A. Lopez-Lago | Chief Scientific Officer | 447,547 | 1970 |
| Giuseppe Del Priore | Chief Medical Officer | 493,048 | 1962 |
| Gadi Levin | Chief Financial Officer & Corporate Secretary | 535,361 | 1973 |
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, currently in Phase 3, dedicated to revolutionizing cancer treatment through its innovative cellular immunotherapies. Its flagship product, Bria-IMT, is currently undergoing a pivotal Phase 3 clinical trial for advanced breast cancer, where it's being evaluated in combination with an immune checkpoint inhibitor. Beyond this lead candidate, the company is also advancing the development of personalized, off-the-shelf treatments designed to combat breast, prostate, and various other forms of cancer. Furthermore, BriaCell maintains a strategic partnership with Incyte Corporation, focused on further evaluating Bria-IMT in combination therapies. The company's operations are headquartered in West Vancouver, Canada.